Form 4 for BCAX Bicara Therapeutics Inc.
Accepted 2025-12-29 00:00:00 ET · period of report 2025-12-26 · accession 0001628280-25-059035 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-12-29 | 2025-12-26 | BCAX | Raben David | Chief Medical Off | M - OptEx | $3.79 | +19.8K | 55.3K | +56% | +$75.0K |
| D | 2025-12-29 | 2025-12-26 | BCAX | Raben David | Chief Medical Off | M - OptEx | $0.00 | -19.8K | 99.0K | -17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-26 | M | A | 19,789 | $3.79 | 55,286 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2025-12-26 | M | D | 19,789 | $0.00 | 98,987 | D | $3.79 · — to 2033-08-08 | 19,789 Common Stock | (F2) 25% of the shares underlying this option vested on July 24, 2024, with the remainder vesting in twelve equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |